Search global stocks & ETFs...Ctrl K
Learn Mode
SRRK
Stock Profile
08-04
Recommended Metric
Score Card
Explore Scores Tab
2.33
Bad
Valuation Score
Key Score
5.00
Very Good
Management
2.00
Bad
Growth
--
--
Profitability
1.00
Very Bad
Fin. Health
4.00
Good
Dividends
--
--
Analyst
2.00
Bad
Insider Transactions
Explore Insider Tab ›Buy Transactions
Sell Transactions
Peers
Select stocks to compare
Price Targets & Ratings
View Analysis
1-year price targets, ending May 11, 2027
Current
$54.88
Baseline
High
$73.50
▲
33.93%
Avg
$60.86
▲
10.90%
Low
$48.48
▼
-11.66%
Analyst Ratings based on 24 Analysts
Strong Buy
938%
Buy
1458%
Hold
104%
Sell
000%
Strong Sell
000%
Scholar Rock Holding Corp. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 289 full-time employees. The company went IPO on 2018-05-24. The firm focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe and debilitating neuromuscular diseases. Its pipeline product candidates include apitegromab, a subcutaneous formulation of apitegromab, and SRK-439. The Apitegromab is an investigational fully human, intravenously administered monoclonal antibody designed to inhibit myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. The SRK-439, is an investigational, subcutaneously administered fully human anti-pro/latent myostatin antibody that has high inhibitory potency while maintaining selectivity towards myostatin. Its early-stage pipeline includes additional programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases.Read More